A drug link assembly unit has a specific linker structure. Connecting the drug link assembly unit to an antibody forms a targeted linker-drug conjugate. The targeted linker-drug conjugate having the specific linker structure is low in polymer content and naked antibody percentage and proper in DAR value, exhibits excellent plasma stability, storage stability and anti-tumor effect, and has a wide application prospect in preparation of drugs for preventing and/or treating tumors.